Epiloid Biotechnology
Epiloid Biotechnology specializes in 3D human brain organoid testing to predict the preclinical efficacy of neurological drugs. By utilizing human-derived organoids, the company addresses the high failure rate and significant costs associated with traditional preclinical models in drug development.
- Biotechnology
Funding
Raised to date
$30KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional preclinical models for neurological drug development often fail to accurately predict efficacy and toxicity in humans, leading to high failure rates and substantial costs. The limitations of animal models and cell cultures in replicating the complexity of the human brain contribute to this translational gap.
Solution
Epiloid Biotechnology offers 3D human brain organoid testing services to improve the prediction of preclinical efficacy for neurological drugs. By utilizing human-derived organoids, Epiloid provides a more relevant and physiologically accurate model of the human brain compared to traditional methods. This approach allows for a more reliable assessment of drug candidates, potentially reducing the risk of failure in later clinical stages and lowering overall drug development costs. Epiloid's services aim to bridge the gap between preclinical research and clinical outcomes in the development of neurological therapies.
Target Audience
Epiloid's primary customers are pharmaceutical and biotechnology companies involved in the development of neurological drugs.
Features
- 3D human brain organoid models derived from human cells
- Assessment of drug efficacy and toxicity in a human-relevant system
- Customized organoid models for specific neurological diseases
- Analysis of organoid structure and function to evaluate drug effects